Zacks Research Issues Optimistic Forecast for BDX Earnings

Becton, Dickinson and Company (NYSE:BDX) – Stock analysts at Zacks Research upped their Q3 2026 earnings estimates for Becton, Dickinson and Company in a report issued on Tuesday, January 21st. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings per share of $4.02 for the quarter, up from their prior forecast of $4.01. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.42 per share.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the company posted $3.42 earnings per share. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis.

Several other research firms have also recently weighed in on BDX. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Evercore ISI boosted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $283.50.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $238.41 on Thursday. The stock has a market cap of $69.14 billion, a P/E ratio of 40.24, a P/E/G ratio of 1.74 and a beta of 0.39. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The company’s 50 day moving average price is $227.44 and its two-hundred day moving average price is $232.83. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $248.42.

Institutional Trading of Becton, Dickinson and Company

Several large investors have recently bought and sold shares of BDX. AE Wealth Management LLC lifted its position in Becton, Dickinson and Company by 36.2% during the 2nd quarter. AE Wealth Management LLC now owns 2,482 shares of the medical instruments supplier’s stock valued at $580,000 after acquiring an additional 660 shares during the period. Thrivent Financial for Lutherans increased its stake in Becton, Dickinson and Company by 12.1% during the 2nd quarter. Thrivent Financial for Lutherans now owns 13,806 shares of the medical instruments supplier’s stock valued at $3,227,000 after purchasing an additional 1,490 shares in the last quarter. Gabelli Funds LLC increased its holdings in Becton, Dickinson and Company by 55.6% in the 2nd quarter. Gabelli Funds LLC now owns 21,000 shares of the medical instruments supplier’s stock worth $4,908,000 after buying an additional 7,500 shares in the last quarter. Public Sector Pension Investment Board increased its position in shares of Becton, Dickinson and Company by 70.5% during the 2nd quarter. Public Sector Pension Investment Board now owns 11,166 shares of the medical instruments supplier’s stock valued at $2,610,000 after purchasing an additional 4,617 shares during the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its holdings in Becton, Dickinson and Company by 59.6% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 55,331 shares of the medical instruments supplier’s stock valued at $12,931,000 after buying an additional 20,653 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP David Shan sold 500 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the sale, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Roland Goette sold 4,483 shares of the business’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now owns 24,345 shares in the company, valued at $5,380,488.45. This represents a 15.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock worth $2,210,716 over the last ninety days. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were paid a $1.04 dividend. The ex-dividend date of this dividend was Monday, December 9th. This represents a $4.16 annualized dividend and a yield of 1.74%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.